Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2019)
14 slides from Terumo's investor presentation, May 9, 2019
Slide 1: Review: Ashitaka Shipping Delays / Strengthen Global Operations
“Review: Ashitaka Shipping Delays” “Strengthen Global Operations” Terumo Corporation President and CEO Shinjiro Sato May 9, 2019
Slide 2: Review: Ashitaka Shipping Delays
Review: Ashitaka Shipping Delays © Terumo Corporation 2019/5/9 2/14
Slide 3: Quickly Normalized, Impact Minimized
Quickly Normalized, Impact Minimized Operations: Quick normalization Sterilization: Added chambers, utilized other factories to restore during 2018. Currently 30% surplus capacity Shipping: All backorders from all regions caused by the shipping delays resolved in FY18 Inventory: Steadily opti
Slide 4: Preventive Actions
Preventive Actions Ease overconcentration of production in Ashitaka factory, improve production capacity and efficiency Accelerate capacity expansion for access devices (guidewire etc.) at Vietnam factory Optimization among 4 factories (Yamaguchi, Vietnam, Maryland and Clinical Supply) Accele
Slide 5: Strengthen Global Operations
Strengthen Global Operations © Terumo Corporation 2019/5/9 5/14
Slide 6: Global Production System (31 factories)
Global Production System (31 factories) Cardiac & Vascular General Hospital Blood Management 60% % outside Japan 53% 40% 20% 21% 0% FY99 FY03 FY08 FY13 FY18 © Terumo Corporation 2019/5/9 6/14
Slide 7: Toward Strengthening Global Operations
Toward Strengthening Global Operations Key themes Key measures Increase capacity to meet growth speed 1. Global optimization Improve quality; cost and efficiency 2. Strengthen organization Stable supply; enhance SCM, risk mgmt. 3. Collaboration across businesses Compliance to tightened regulatio
Slide 8: (1) Global Optimization: Cardiac & Vascular TIS Case
(1) Global Optimization: Cardiac & Vascular TIS Case Mother factory Ashitaka Ashitaka Products A B C D A Sub mother factory Maryland Yamaguchi B C Satellite factory Mary‐ Puerto Yama‐ Puerto Hanoi Hanoi land Rico guchi Rico Products A B C D B D C D © Terumo Corporation 2019/5/9 8/14
Slide 9: (2) Strengthen Organization
(2) Strengthen Organization Cardiac General Blood & Vascular Hospital Management Chief Quality systems, regulatory, Existing Quality Officer environmental compliance Chief New Manufacturing Global optimization, capacity expansion Officer Improve productivity Stable supply TIS‐dedicated Chief Product
Slide 10: (3) Collaboration Across Businesses/Companies Cases
(3) Collaboration Across Businesses/Companies Cases Flexible sharing of sterilization functionality Maryland Ashitaka Fujinomiya Hanoi Sharing of production technology Terumo BCT (US) Robotic production Kofu Acquired factory process transfer, integration Bolton Medical Stent graft Hanoi Acce
Slide 11: (4) Local Production: China Case
(4) Local Production: China Case Essen Technology Co., Ltd. acquisition (completed Dec ’18) Obtained made‐in‐China DES; biggest market in near future Collaborate with Terumo engineers to improve production and Drug‐eluting stent "Tivoli" development technologies Established peritoneal dialys
Slide 12: Monozukuri Evolution: From Implicit to Explicit; Pass on within The Group
Monozukuri Evolution: From Implicit to Explicit; Pass on within The Group Make engineering expertise explicit and share Mutual learning across businesses/companies Visualize and analyze craftsmanship by IT Onsite trainings, Utilize eye‐tracking opinion exchanges technology Efficiently enhanc
Slide 13: Mid- to Long Term Vision
Mid‐ to Long Term Vision Trusted in medical settings as a Top Brand World‐class total Quality (products, supply, services) Global Corporation with Unique Excellence © Terumo Corporation 2019/5/9 13/14
Slide 14: IR Contact
IR Contact Terumo Corporation Corporate Communication (IR) Dept. E‐mail: [email protected] Among the information that Terumo discloses, the forward‐looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i